RU96105951A - PHARMACEUTICAL COMPOSITIONS WITH THE NERVE GROWTH FACTOR - Google Patents

PHARMACEUTICAL COMPOSITIONS WITH THE NERVE GROWTH FACTOR

Info

Publication number
RU96105951A
RU96105951A RU96105951/14A RU96105951A RU96105951A RU 96105951 A RU96105951 A RU 96105951A RU 96105951/14 A RU96105951/14 A RU 96105951/14A RU 96105951 A RU96105951 A RU 96105951A RU 96105951 A RU96105951 A RU 96105951A
Authority
RU
Russia
Prior art keywords
composition
growth factor
nerve growth
composition according
water
Prior art date
Application number
RU96105951/14A
Other languages
Russian (ru)
Other versions
RU2126265C1 (en
Inventor
М.Кнепп Виктория
М.Лидгейт Дебора
Маскивич Ричард
Гу Лео
Original Assignee
Синтекс (Ю.ЭС.ЭЙ.) Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/109,798 external-priority patent/US6277828B1/en
Application filed by Синтекс (Ю.ЭС.ЭЙ.) Инк. filed Critical Синтекс (Ю.ЭС.ЭЙ.) Инк.
Publication of RU96105951A publication Critical patent/RU96105951A/en
Application granted granted Critical
Publication of RU2126265C1 publication Critical patent/RU2126265C1/en

Links

Claims (14)

1. Водная фармацевтическая композиция, включающая: (а) фактор роста нервов; (б) биологически приемлемую соль в количестве, достаточном для поддержания изотоничности; (в) буфер в количестве, достаточном для поддержания рН композиции на уровне от приблизительно 4,5 до приблизительно 6,0; и (г) воду.1. An aqueous pharmaceutical composition comprising: (a) nerve growth factor; (b) a biologically acceptable salt in an amount sufficient to maintain isotonicity; (c) a buffer in an amount sufficient to maintain the pH of the composition at a level of from about 4.5 to about 6.0; and (d) water. 2. Композиция по п. 1, дополнительно включающая биологически приемлемый, водорастворимый носитель. 2. The composition of claim 1, further comprising a biologically acceptable, water soluble carrier. 3. Композиция по п.1 или 2, в которой: (а) фактор роста нервов составляет от приблизительно 0,0001 до приблизительно 0,125 вес.% водной композиции; (б) носитель составляет от приблизительно 0,1 до приблизительно 1,25 вес.% водной композиции; (в) соль составляет от приблизительно 0,5 до приблизительно 1,0 вес.% водной композиции; и (г) буфер присутствует в количестве, достаточном для поддержания рН водной композиции на уровне от приблизительно 4,5 до приблизительно 6,0. 3. The composition according to claim 1 or 2, in which: (a) the nerve growth factor is from about 0.0001 to about 0.125 wt.% The aqueous composition; (b) the carrier comprises from about 0.1 to about 1.25% by weight of the aqueous composition; (c) the salt comprises from about 0.5 to about 1.0 wt.% the aqueous composition; and (g) the buffer is present in an amount sufficient to maintain the pH of the aqueous composition at a level of from about 4.5 to about 6.0. 4. Композиция по любому из пп. 1-3, где значение рН равно от приблизительно 5,0 до приблизительно 5,4. 4. The composition according to any one of paragraphs. 1-3, where the pH value is from about 5.0 to about 5.4. 5. Водная композиция по любому из пп. 2 - 4, включающая от 10 до 500 мкг/мл фактора роста нервов, 5 мг/мл сывороточного альбумина человека, 8,7 мг/мл NaCl, 2,1 мг/мл лимонной кислоты и воду и где значение рН данной композиции установлено на уровне приблизительно 5,2. 5. The aqueous composition according to any one of paragraphs. 2 to 4, including 10 to 500 μg / ml nerve growth factor, 5 mg / ml human serum albumin, 8.7 mg / ml NaCl, 2.1 mg / ml citric acid and water, and where the pH value of this composition is set to level of approximately 5.2. 6. Водная фармацевтическая композиция с фактором роста нервов, пригодная для лиофилизации, включающая: (а) фактор роста нервов; (б) биологически приемлемый наполнитель; (в) буфер в количестве, достаточном для поддержания рН композиции на уровне от приблизительно 5,5 до приблизительно 6,5; и (г) воду. 6. An aqueous pharmaceutical composition with nerve growth factor suitable for lyophilization, including: (a) nerve growth factor; (b) a biologically acceptable excipient; (c) a buffer in an amount sufficient to maintain the pH of the composition at a level of from about 5.5 to about 6.5; and (d) water. 7. Композиция по п.6, включающая от 1 до 1250 мкг/мл фактора роста нервов и от 30 до 90 мг/мл наполнителя. 7. The composition according to claim 6, comprising from 1 to 1250 μg / ml nerve growth factor and from 30 to 90 mg / ml excipient. 8. Композиция по п.6 или 7, где наполнителем является сахар. 8. The composition according to claim 6 or 7, where the filler is sugar. 9. Композиция по любому из пп.6 - 8, где наполнитель включает смесь сахарозы и маннита, буфер является цитратом и значение рН композиции равно от приблизительно 5,8 до приблизительно 6,2. 9. The composition according to any one of claims 6 to 8, wherein the excipient comprises a mixture of sucrose and mannitol, the buffer is citrate, and the pH of the composition is from about 5.8 to about 6.2. 10. Композиция по любому из пп.6 - 9, лиофилизированная для уменьшения содержания влаги до уровня ниже приблизительно 2%. 10. The composition according to any one of claims 6 to 9, lyophilized to reduce the moisture content to below about 2%. 11. Лиофилизированнный фармацевтический состав, включающий от 0,001 до 1,25 частей фактора роста нервов, от 30 до 90 частей сахара и менее приблизительно 1 части воды. 11. A lyophilized pharmaceutical composition comprising from 0.001 to 1.25 parts of nerve growth factor, from 30 to 90 parts of sugar, and less than about 1 part of water. 12. Композиция или состав по любому из пп.6 - 11, дополнительно включающая биологически приемлемый водорастворимый носитель. 12. The composition or composition according to any one of claims 6 to 11, further comprising a biologically acceptable water-soluble carrier. 13. Композиция или состав по любому из пп. 1-12 для применения при лечении нейронной дисфункции у людей. 13. The composition or composition according to any one of paragraphs. 1-12 for use in the treatment of neural dysfunction in humans. 14. Композиция или состав по п. 13 в форме для интрацеребровентрикулярного вливания для применения при лечении болезни Альцгеймера у людей. 14. The composition or composition of claim 13 in an intracerebroventricular infusion form for use in the treatment of Alzheimer's disease in humans.
RU96105951A 1993-08-20 1994-08-16 Pharmaceutical compositions with nerve growth factors RU2126265C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/109,798 US6277828B1 (en) 1993-08-20 1993-08-20 Pharmaceutical formulations of nerve growth factor
US08/109.798 1993-08-20
PCT/US1994/009245 WO1995005845A1 (en) 1993-08-20 1994-08-16 Pharmaceutical formulations of nerve growth factor

Publications (2)

Publication Number Publication Date
RU96105951A true RU96105951A (en) 1998-06-10
RU2126265C1 RU2126265C1 (en) 1999-02-20

Family

ID=22329623

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96105951A RU2126265C1 (en) 1993-08-20 1994-08-16 Pharmaceutical compositions with nerve growth factors

Country Status (32)

Country Link
US (2) US6277828B1 (en)
EP (1) EP0721343B1 (en)
JP (2) JP4592830B2 (en)
KR (1) KR100341193B1 (en)
CN (1) CN1163265C (en)
AT (1) ATE226085T1 (en)
AU (1) AU677699B2 (en)
BG (1) BG62951B1 (en)
BR (1) BR9407278A (en)
CA (1) CA2169834C (en)
CZ (1) CZ292422B6 (en)
DE (1) DE69431562T2 (en)
DK (1) DK0721343T3 (en)
ES (1) ES2181723T3 (en)
FI (1) FI113241B (en)
HK (1) HK1012990A1 (en)
HU (1) HU228152B1 (en)
IL (3) IL124941A (en)
LT (1) LT4051B (en)
LV (1) LV11279B (en)
NO (1) NO317627B1 (en)
NZ (1) NZ271873A (en)
PL (1) PL176387B1 (en)
PT (1) PT721343E (en)
RO (1) RO114742B1 (en)
RU (1) RU2126265C1 (en)
SI (1) SI9420048B (en)
SK (1) SK284064B6 (en)
TW (1) TW427905B (en)
UA (1) UA43348C2 (en)
WO (1) WO1995005845A1 (en)
ZA (1) ZA946333B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
EP0831883A1 (en) * 1995-05-12 1998-04-01 The Rockefeller University Treatment of alzheimer disease by modulation of synapsins
AU721112B2 (en) * 1995-11-07 2000-06-22 Genentech Inc. Stabilizing formulation for NGF
US6964947B1 (en) * 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
WO1997045009A2 (en) * 1996-05-29 1997-12-04 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
CN1059597C (en) * 1996-08-08 2000-12-20 陈素兰 Nerve injury recovery preparation
AU727652B2 (en) * 1997-05-01 2000-12-21 Protechtion Unlimited, Inc. Nerve growth factor as a vaccine adjuvant
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
CA2304720A1 (en) * 1997-09-30 1999-04-08 Duke University Apolipoprotein e/growth factor complexes and methods of use
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
KR20040065278A (en) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 Liquid composition of modified factor vii polypeptides
JP2005530683A (en) * 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Liquid composition of factor VII polypeptide
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PL207018B1 (en) 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Stabilised solid compositions of factor vii polypeptides
MXPA05009914A (en) * 2003-03-18 2006-01-09 Novo Nordisk Healthcare Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides.
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
CA2525224A1 (en) * 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
CN1318087C (en) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 Removing albumin nerve growth factor agent
ATE547114T1 (en) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag LIQUID COMPOSITIONS OF FACTOR VII POLYPEPTIDES
EP1644030B1 (en) * 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
KR20120104619A (en) * 2003-08-14 2012-09-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Liquid, aqueous pharmaceutical composition of factor vii polypeptides
CN1917861B (en) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 Stabilised compositions of factor vii polypeptides
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US20090325978A1 (en) * 2006-08-14 2009-12-31 Katsumi Onai Stable lyophilized preparation
ES2549790T3 (en) * 2006-11-08 2015-11-02 P Mind Co., Ltd Apparatus for accelerating the production of neurotrophic factor
EP1958618A1 (en) 2007-02-15 2008-08-20 Octapharma AG Method for freeze-drying with optimum reconstitution of biopolymers
KR20110061639A (en) * 2008-09-26 2011-06-09 아도시아 Complex consisting of polysaccharide and an hpb
CN102232932B (en) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 Pectin-adriamycin coniuncate lyophilized preparation, and preparation method thereof
AU2012238643B2 (en) 2011-04-07 2017-04-13 Neovacs Method for treating IFNalpha related conditions
EP2812019A1 (en) * 2012-02-08 2014-12-17 Institut National De La Recherche Agronomique Use of beta-nerve growth factor for inducing ovulation in mammals
DK3287139T3 (en) * 2015-04-21 2021-09-13 Beijing Staidson Medical Tech Co Ltd Nerve growth factor composition and injection powder
WO2016169454A1 (en) * 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 Nerve growth factor composition and powder injection
EP3287141B1 (en) * 2015-04-21 2021-08-18 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and injection powder
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
EP3434283A4 (en) 2016-03-25 2019-11-13 Astellas Pharma Inc. Medicinal composition comprising peg anti-human ngf antibody fab' fragment
PT3463308T (en) * 2016-06-01 2022-03-11 Servier Ip Uk Ltd Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN109260147B (en) * 2018-10-15 2019-09-13 珠海亿胜生物制药有限公司 It is a kind of for treating or preventing the recombination human basic fibroblast growth factor injection of neurotrosis
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packages comprising polypropylene containers and ngf aqueous formulations packaged therein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222413A (en) 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (en) * 1988-03-18 1990-05-24 Fidia Farmaceutici USE OF THE HUMAN NERVE GROWTH FACTOR AND ITS PHARMACEUTICAL COMPOSITIONS
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0418031A (en) * 1989-02-16 1992-01-22 Hiroshi Saito Injury healing promoter
JP3283288B2 (en) * 1991-03-08 2002-05-20 電気化学工業株式会社 Bioactive peptide preparation
JP2818834B2 (en) * 1991-08-12 1998-10-30 大塚製薬株式会社 IL-1α stabilized pharmaceutical preparation

Similar Documents

Publication Publication Date Title
RU96105951A (en) PHARMACEUTICAL COMPOSITIONS WITH THE NERVE GROWTH FACTOR
SI9420048B (en) Pharmaceutical formulations of nerve growth factor
DE69532970T2 (en) SPRAY-DRYED ERYTHROPOIETIN
US4760051A (en) Use of GHL-Cu as a wound-healing and anti-inflammatory agent
CA2288143A1 (en) Activated protein c formulations
DE68905886T2 (en) CALCITON COMPOSITION FOR INTRANASAL ADMINISTRATION.
RU99118890A (en) WATER-SOLUBLE PHARMACEUTICAL COMPOSITION IN THE FORM OF ION COMPLEX AND ITS APPLICATION
DE69921175T2 (en) HEXAPEPTIDES WITH STABILIZED DISULFIDE BINDING AND ITS DERIVATIVES FOR REGULATING METABOLISM, PROLIFERATION, DIFFERENTIATION AND APOPTOSIS
JP2001010960A (en) Topcal zinc composition
WO1986003493A1 (en) Hirudin-pa and derivatives thereof, process for the production a nd utilization thereof
CA2058835A1 (en) Stable pharmaceutical composition and method for its production
RU2001130142A (en) Pharmaceutical Compositions of Erythropoietin
JPS6326120B2 (en)
JPH08245417A (en) Pharmaceutical noninorganic salt solution for intranasal administration
EP0130619A2 (en) Hepatitis B vaccine and method for its preparation
DE04007657T1 (en) Pharmaceutical composition of fibrinolytic agent
SK283021B6 (en) Production method for sterile cetrorelix lyophilisate
DE69925820T2 (en) PREPARATIONS FOR STABILIZING PEG-INTERFERON ALPHA CONJUGATES
DE69525955T2 (en) A PHARMACEUTICAL FORMULATION CONTAINING GROWTH HORMONE AND ISOLEUCIN
KR19990064322A (en) Stable pharmaceutical dosage preparations containing parathyroid hormone
KR900015749A (en) Interleukin-1 formulation
DE69524965T2 (en) GROWTH HORMONE AND VALIN CONTAINING MEDICINAL PRODUCTS
FI98122B (en) A process for preparing a lipid metabolism promoting agent
AU689603B2 (en) A pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof
DE69531166T2 (en) MEDICINAL PRODUCT TO RELEASE THE SIDE EFFECTS CAUSED BY IMMUNE SUPPRESSIVA